FUS (RNA-binding protein FUS) variants and mutations
FUS (also known as RNA-binding protein FUS) is a human protein-coding gene encoding a RNA-binding protein. It coordinates transcription, RNA processing, transport, and stress-granule dynamics and can shuttle between nucleus and cytoplasm. Pathogenic variants can cause amyotrophic lateral sclerosis through disturbed RNA and protein homeostasis and are also associated with frontotemporal degeneration. This analysis covers 759 FUS variants and mutations. Of these, 74% have computational variant effect predictions. Disease context includes sporadic amyotrophic lateral sclerosis, amyotrophic lateral sclerosis, and frontotemporal dementia with motor neuron disease. Example FUS variants include A2T, A2S, and A2A.
Variant analysis overview
- Gene: FUS
- Protein: RNA-binding protein FUS
- UniProt accession: P35637
- Organism: Homo sapiens
- Variants analyzed: 759
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 597 unspecified-consequence records; 63 missense variants; 74 synonymous variants; 4 stop-gained variants; 4 splice-region variants; 7 in-frame deletions; 2 frameshift variants; 6 substitution
- Prediction scores: 558 variants have prediction scores (74% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: sporadic amyotrophic lateral sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia with motor neuron disease, essential tremor, juvenile amyotrophic lateral sclerosis, hereditary disease, liposarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, extraskeletal myxoid chondrosarcoma, leiomyosarcoma, lipoma.
Protein structure and variant hotspots
- Protein features: 1 domains; 33 post-translational modification sites.
- Structural context: 38 variants have structural context.
- PTM context: 64 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable FUS variants
Examples include A2T, A2S, A2A, S3*, S3S, N4N, N4K, D5G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), TOPMed rs1429657204, REVEL 0.39, CADD 26.10
- A2S (p.Ala2Ser), gnomAD 16-31180218-G-T, REVEL 0.35, CADD 25.90
- A2A (p.Ala2Ala), rs549671130, gnomAD 16-31180220-C-G, CADD 13.90
- S3* (p.Ser3Ter), gnomAD 16-31180222-C-A, CADD 38.00
- S3S (p.Ser3Ser), rs890291931, gnomAD 16-31180223-A-G, CADD 16.40
- N4N (p.Asn4Asn), gnomAD 16-31180226-C-T, CADD 22.80
- N4K (p.Asn4Lys), gnomAD 16-31180226-C-A, REVEL 0.35, CADD 24.10
- D5G (p.Asp5Gly), cosmic curated COSV10583, ExAC rs778010613, gnomAD rs778010613, REVEL 0.45, CADD 26.50, Uncertain significance, Inborn genetic diseases
- D5N (p.Asp5Asn), gnomAD rs1416835498
- D5A (p.Asp5Ala), gnomAD 16-31182398-A-C, REVEL 0.39, CADD 26.10
- Y6F (p.Tyr6Phe), Ensembl rs2144100866
- Y6H (p.Tyr6His), TOPMed rs967554455, REVEL 0.56, CADD 29.90
- Y6D (p.Tyr6Asp), gnomAD 16-31182400-T-G, REVEL 0.69, CADD 31.00
- T7A (p.Thr7Ala), ExAC rs753775282, gnomAD rs753775282, REVEL 0.34, CADD 23.00
- T7S (p.Thr7Ser), TOPMed rs978032980, gnomAD rs978032980, REVEL 0.21, CADD 16.20
- T7I (p.Thr7Ile), gnomAD 16-31182404-C-T, REVEL 0.42, CADD 23.20
- T7T (p.Thr7Thr), gnomAD 16-31182405-C-T, CADD 9.81
- Q8Q (p.Gln8Gln), rs202111940, gnomAD 16-31182408-A-G, CADD 13.30
- Q9E (p.Gln9Glu), Ensembl rs2079192900, REVEL 0.18, CADD 23.10
- Q9R (p.Gln9Arg), gnomAD rs2079192932, REVEL 0.29, CADD 24.00
- A10S (p.Ala10Ser), TOPMed rs2079193002
- T11A (p.Thr11Ala), rs750230722, ClinGen CA8023413, ClinVar RCV000517990, ExAC rs750230722, REVEL 0.24, CADD 20.90, Uncertain significance, not specified
- T11S (p.Thr11Ser), ExAC rs750230722, TOPMed rs750230722, gnomAD rs750230722, REVEL 0.24, CADD 22.80, Uncertain significance
- T11I (p.Thr11Ile), gnomAD 16-31182416-C-T, REVEL 0.40, CADD 22.80
- T11T (p.Thr11Thr), gnomAD 16-31182417-C-A, CADD 14.10
- Q12E (p.Gln12Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q12H (p.Gln12His), gnomAD 16-31182420-A-T, REVEL 0.45, CADD 32.00
- S13S (p.Ser13Ser), rs1159077451, gnomAD 16-31182513-C-T, CADD 16.20
- Y14C (p.Tyr14Cys), rs758073877, ClinGen CA8023435, ClinVar RCV003420751, ExAC rs758073877, REVEL 0.59, CADD 28.60, Uncertain significance, FUS-related disorder
- Y14N (p.Tyr14Asn), rs2079194587, ClinGen CA395664566, ClinVar RCV001120231, Ensembl rs2079194587, AlphaMissense 0.46, MetaLR 0.73, Uncertain significance, Amyotrophic lateral sclerosis type 6
- Y14F (p.Tyr14Phe), gnomAD 16-31182515-A-T, REVEL 0.39, CADD 26.10
- Y14Y (p.Tyr14Tyr), rs1397618700, gnomAD 16-31182516-T-C, CADD 15.70
- G15R (p.Gly15Arg), TOPMed rs1461699398
- A16G (p.Ala16Gly), 1000Genomes rs139980267, ESP rs139980267, ExAC rs139980267, TOPMed rs139980267, Likely benign
- A16T (p.Ala16Thr), gnomAD rs2079194811, REVEL 0.46, CADD 22.20
- A16V (p.Ala16Val), rs139980267, ClinGen CA8023436, ClinVar RCV002099375, ClinVar RCV002337173, REVEL 0.45, CADD 23.20, Likely benign, Inborn genetic diseases; Amyotrophic lateral sclerosis type 6; Tremor, hereditar
- A16S (p.Ala16Ser), gnomAD 16-31182520-G-T, REVEL 0.30, CADD 21.20
- A16A (p.Ala16Ala), gnomAD 16-31182522-C-G, CADD 17.10
- Y17* (p.Tyr17Ter), TOPMed rs2079194986
- Y17H (p.Tyr17His), TOPMed rs2079194905
- Y17S (p.Tyr17Ser), ExAC rs746625098, TOPMed rs746625098, gnomAD rs746625098, REVEL 0.61, CADD 31.00
- Y17Y (p.Tyr17Tyr), gnomAD 16-31182525-C-T, CADD 18.30
- P18A (p.Pro18Ala), 1000Genomes rs144888138, ESP rs144888138, ExAC rs144888138, TOPMed rs144888138, Likely benign
- P18S (p.Pro18Ser), rs144888138, ClinGen CA8023439, ClinVar RCV001120232, ClinVar RCV001247861, REVEL 0.32, CADD 22.40, Uncertain significance, Amyotrophic lateral sclerosis type 6; Tremor, hereditary essential, 4
- P18T (p.Pro18Thr), rs144888138, ClinGen CA8023438, cosmic curated COSV99568, ClinVar RCV001440763, REVEL 0.38, CADD 21.30, Likely benign, Amyotrophic lateral sclerosis type 6; Tremor, hereditary essential, 4
- P18P (p.Pro18Pro), gnomAD 16-31182528-C-G, CADD 19.20
- T19P (p.Thr19Pro), gnomAD rs1458127703, REVEL 0.45, CADD 24.60
- T19S (p.Thr19Ser), gnomAD rs1310122649, REVEL 0.19, CADD 21.70, Uncertain significance, Inborn genetic diseases
- T19T (p.Thr19Thr), rs2079195634, gnomAD 16-31182531-C-T, CADD 18.50
- Q20H (p.Gln20His), gnomAD 16-31182534-G-C, REVEL 0.46, CADD 23.00
- P21H (p.Pro21His), gnomAD rs1240131317
- P21L (p.Pro21Leu), gnomAD rs1240131317
- P21T (p.Pro21Thr), gnomAD rs1319178925, REVEL 0.44, CADD 23.50
- P21S (p.Pro21Ser), gnomAD 16-31182535-C-T, REVEL 0.32, CADD 22.50
- P21P (p.Pro21Pro), rs984488116, gnomAD 16-31182537-C-G, CADD 15.40
- G22R (p.Gly22Arg), gnomAD rs1260673954, REVEL 0.45, CADD 24.70
- G22G (p.Gly22Gly), rs147877613, gnomAD 16-31182540-G-A, CADD 16.80
- Q23* (p.Gln23Ter), NCI-TCGA Cosmic COSV5421, cosmic curated COSV54218, Variant assessed as somatic; high impact.
- Q23L (p.Gln23Leu), gnomAD 16-31182542-A-T, REVEL 0.65, CADD 29.70
- G24V (p.Gly24Val), gnomAD rs867096546, REVEL 0.67, CADD 29.20
- G24D (p.Gly24Asp), gnomAD 16-31182545-G-A, REVEL 0.57, CADD 29.40
- G24G (p.Gly24Gly), rs771420721, gnomAD 16-31182546-C-A, CADD 19.00
- Y25C (p.Tyr25Cys), ESP rs141516414, ExAC rs141516414, TOPMed rs141516414, gnomAD rs141516414, REVEL 0.69, CADD 32.00, Uncertain significance, not provided
- Y25S (p.Tyr25Ser), rs141516414, ClinGen CA280592003, ClinVar RCV003384778, ESP rs141516414, REVEL 0.62, CADD 32.00, Uncertain significance, Inborn genetic diseases
- Y25* (p.Tyr25Ter), gnomAD 16-31182549-T-G, CADD 35.00
- S26P (p.Ser26Pro), gnomAD 16-31182550-T-C, REVEL 0.43, CADD 28.70
- S26F (p.Ser26Phe), gnomAD 16-31182551-C-T, REVEL 0.45, CADD 27.50
- S26C (p.Ser26Cys), gnomAD 16-31182551-C-G, REVEL 0.43, CADD 26.90
- Q27Q (p.Gln27Gln), gnomAD 16-31182555-G-A, CADD 20.00
- Q28Q (p.Gln28Gln), gnomAD 16-31182558-G-A, CADD 21.60
- S29N (p.Ser29Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S30G (p.Ser30Gly), 1000Genomes rs2144101604, REVEL 0.27, CADD 23.30
- S30I (p.Ser30Ile), Ensembl rs2144101617, REVEL 0.29, CADD 7.19
- S30N (p.Ser30Asn), gnomAD 16-31182563-G-A, REVEL 0.15, CADD 3.49
- S30S (p.Ser30Ser), rs1485377976, gnomAD 16-31182564-T-C, CADD 17.30
- P32L (p.Pro32Leu), rs1316860525, ClinGen CA395664797, ClinVar RCV004387293, TOPMed rs1316860525, REVEL 0.40, CADD 24.70, Uncertain significance, Inborn genetic diseases
- P32S (p.Pro32Ser), gnomAD 16-31182568-C-T, REVEL 0.14, MetaLR 0.38
- P32P (p.Pro32Pro), rs932534102, gnomAD 16-31182570-C-T, CADD 17.80
- Y33H (p.Tyr33His), Ensembl rs17852338
- Y33D (p.Tyr33Asp), gnomAD 16-31182571-T-G, REVEL 0.53, MetaLR 0.71
- Y33Y (p.Tyr33Tyr), rs371503663, gnomAD 16-31182573-C-T, CADD 6.68
- G34E (p.Gly34Glu), cosmic curated COSV10728, Ensembl rs1567469634, REVEL 0.48, CADD 24.90, Uncertain significance, Amyotrophic lateral sclerosis type 6; Tremor, hereditary essential, 4
- G34R (p.Gly34Arg), gnomAD 16-31182574-G-A, REVEL 0.45, MetaLR 0.71
- Q35L (p.Gln35Leu), gnomAD 16-31182578-A-T, REVEL 0.48, MetaLR 0.68
- Q36E (p.Gln36Glu), TOPMed rs1443603626
- Q36H (p.Gln36His), ExAC rs772271532, TOPMed rs772271532, gnomAD rs772271532, REVEL 0.48, CADD 27.50
- S37G (p.Ser37Gly), gnomAD 16-31182583-A-G, REVEL 0.21, MetaLR 0.33
- S37N (p.Ser37Asn), gnomAD 16-31182584-G-A, REVEL 0.41, MetaLR 0.66
- Y38S (p.Tyr38Ser), gnomAD 16-31182587-A-C, REVEL 0.61, MetaLR 0.69
- S39G (p.Ser39Gly), TOPMed rs1185199662
- G40A (p.Gly40Ala), rs147066627, ClinGen CA8023445, ClinVar RCV002346886, ClinVar RCV003096699, REVEL 0.41, CADD 20.50, Likely benign, Inborn genetic diseases; Amyotrophic lateral sclerosis type 6; Tremor, hereditar
- G40R (p.Gly40Arg), gnomAD 16-31182592-G-C, REVEL 0.59, MetaLR 0.52
- Y41H (p.Tyr41His), gnomAD 16-31182595-T-C, REVEL 0.57, MetaLR 0.72
- Y41Y (p.Tyr41Tyr), rs1379647437, gnomAD 16-31182597-T-C, CADD 4.50
- S42G (p.Ser42Gly), gnomAD 16-31182598-A-G, REVEL 0.09, MetaLR 0.12
- S42S (p.Ser42Ser), rs760946772, gnomAD 16-31182600-C-T, CADD 12.90
- Q43K (p.Gln43Lys), TOPMed rs1247281589, REVEL 0.52, CADD 23.20
- Q43L (p.Gln43Leu), gnomAD 16-31182602-A-T, REVEL 0.64, MetaLR 0.58
- S44A (p.Ser44Ala), TOPMed rs2079196497
- S44F (p.Ser44Phe), gnomAD 16-31182605-C-T, REVEL 0.41, MetaLR 0.61
- S44S (p.Ser44Ser), rs72550883, gnomAD 16-31182606-C-T, CADD 12.10
- T45M (p.Thr45Met), ExAC rs776850144, TOPMed rs776850144, gnomAD rs776850144, REVEL 0.22, CADD 21.20
- T45A (p.Thr45Ala), gnomAD 16-31182607-A-G, REVEL 0.07, MetaLR 0.12
- T45T (p.Thr45Thr), gnomAD 16-31182609-G-C, CADD 2.08
- D46E (p.Asp46Glu), ExAC rs761920392, gnomAD rs761920392, REVEL 0.12, CADD 11.70
- D46H (p.Asp46His), NCI-TCGA Cosmic COSV5421, cosmic curated COSV54215, Variant assessed as somatic; moderate impact.
- T47S (p.Thr47Ser), gnomAD rs1300722518, REVEL 0.29, CADD 20.90
- T47P (p.Thr47Pro), gnomAD 16-31182613-A-C, REVEL 0.49, MetaLR 0.59
- T47I (p.Thr47Ile), gnomAD 16-31182614-C-T, REVEL 0.49, MetaLR 0.65
- S48L (p.Ser48Leu), gnomAD rs2079196677, REVEL 0.48, CADD 28.50
- S48P (p.Ser48Pro), Ensembl rs2144101816
- S48S (p.Ser48Ser), rs80060438, gnomAD 16-31182618-A-G, CADD 16.70
- G49G (p.Gly49Gly), rs741810, gnomAD 16-31182621-C-T, CADD 18.80
- Y50C (p.Tyr50Cys), rs1480335769, gnomAD rs1480335769, REVEL 0.66, CADD 30.00, Variant assessed as somatic; moderate impact.
- G51D (p.Gly51Asp), gnomAD rs1306780434, REVEL 0.65, CADD 26.80
- G51G (p.Gly51Gly), rs61733962, gnomAD 16-31182627-C-T, CADD 18.30
- S53G (p.Ser53Gly), TOPMed rs1247098643, REVEL 0.36, CADD 25.20
- S53I (p.Ser53Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S53N (p.Ser53Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S54N (p.Ser54Asn), rs754613619, ClinGen CA8023455, ClinVar RCV003188393, ExAC rs754613619, REVEL 0.25, CADD 21.90, Likely benign, Inborn genetic diseases
- p.Ser54 Ser61del, gnomAD 16-31182621-CTATG, CADD 22.70
- S54S (p.Ser54Ser), rs1268890915, gnomAD 16-31182636-C-T, CADD 18.90
- Y55C (p.Tyr55Cys), rs1596890201, ClinGen CA395665174, ClinVar RCV002403631, NCI-TCGA TCGA novel, REVEL 0.55, CADD 27.80, Uncertain significance, Inborn genetic diseases
- Y55Y (p.Tyr55Tyr), gnomAD 16-31182639-T-C, CADD 11.60
- S56F (p.Ser56Phe), gnomAD rs1347246851, REVEL 0.48, CADD 17.30
- S56S (p.Ser56Ser), rs1327576762, gnomAD 16-31182642-T-C, CADD 16.30
- S57F (p.Ser57Phe), Ensembl rs12446646, REVEL 0.63, CADD 24.00
- S57del (p.Ser57del), rs777545405, gnomAD 16-31182638-ATTC-, CADD 11.20
- S57S (p.Ser57Ser), gnomAD 16-31182645-T-G, CADD 12.60
- Y58C (p.Tyr58Cys), gnomAD 16-31182647-A-G, REVEL 0.53, MetaLR 0.66
- Y58Y (p.Tyr58Tyr), rs780887876, gnomAD 16-31182648-T-C, CADD 0.13
- G59G (p.Gly59Gly), gnomAD 16-31182651-C-G, CADD 13.10
- Q60E (p.Gln60Glu), gnomAD 16-31182652-C-G, REVEL 0.46, MetaLR 0.65
- Q60Q (p.Gln60Gln), gnomAD 16-31182654-G-A, CADD 13.80
- Q60H (p.Gln60His), gnomAD 16-31182654-G-T, REVEL 0.47, MetaLR 0.60
- S61G (p.Ser61Gly), rs1481060391, ClinGen CA395665302, ClinVar RCV001311445, ClinVar RCV003770632, REVEL 0.25, CADD 20.50, Uncertain significance, Tremor, hereditary essential, 4; Amyotrophic lateral sclerosis type 6; not provi
- S61N (p.Ser61Asn), rs777365216, ClinGen CA8023460, ClinVar RCV001035313, ExAC rs777365216, REVEL 0.26, CADD 12.70, Uncertain significance, Amyotrophic lateral sclerosis type 6; Tremor, hereditary essential, 4
- S61S (p.Ser61Ser), rs1396374632, gnomAD 16-31183862-C-T, CADD 6.69
- Q62H (p.Gln62His), gnomAD 16-31182660-G-C, REVEL 0.47, MetaLR 0.31
- N63S (p.Asn63Ser), rs140883211, ClinGen CA8023461, ClinVar RCV000996260, ClinVar RCV001858833, REVEL 0.20, CADD 13.70, Conflicting interpretations, Inborn genetic diseases; not provided; Amyotrophic lateral sclerosis type 6
- T64I (p.Thr64Ile), Ensembl rs2079218032, REVEL 0.36, CADD 23.10
- G65D (p.Gly65Asp), gnomAD rs2079218084, REVEL 0.63, CADD 26.00
- Y66C (p.Tyr66Cys), gnomAD 16-31183864-A-G, REVEL 0.69, MetaLR 0.73
- Y66Y (p.Tyr66Tyr), rs144853447, gnomAD 16-31183865-T-C, CADD 7.88, SIFT 0.11
- T68S (p.Thr68Ser), ExAC rs765041157, gnomAD rs765041157
- Q69E (p.Gln69Glu), gnomAD 16-31183872-C-G, REVEL 0.43, MetaLR 0.67
- Q69R (p.Gln69Arg), gnomAD 16-31183873-A-G, REVEL 0.44, MetaLR 0.65
- Q69Q (p.Gln69Gln), rs1427301192, gnomAD 16-31183874-G-A, CADD 10.30, SIFT 0.07
- S70* (p.Ser70Ter), gnomAD 16-31183876-C-A, CADD 37.00
- S70S (p.Ser70Ser), rs772845268, gnomAD 16-31183877-A-C, CADD 13.40, SIFT 0.09
- T71A (p.Thr71Ala), rs762488475, ClinGen CA8023536, ClinVar RCV002944224, ExAC rs762488475, REVEL 0.15, CADD 10.90, Uncertain significance, Tremor, hereditary essential, 4; Amyotrophic lateral sclerosis type 6
- T71I (p.Thr71Ile), gnomAD rs1486425741
- T71N (p.Thr71Asn), gnomAD 16-31183879-C-A, REVEL 0.32, MetaLR 0.39
- T71T (p.Thr71Thr), rs765998802, gnomAD 16-31183880-T-G, CADD 11.90, SIFT 1.00
- P72A (p.Pro72Ala), ExAC rs753197353, TOPMed rs753197353, gnomAD rs753197353, REVEL 0.47, CADD 21.50
- P72L (p.Pro72Leu), rs2144107259, ClinGen CA395666497, ClinVar RCV001880616, Ensembl rs2144107259, AlphaMissense 0.23, MetaLR 0.75, Uncertain significance, Amyotrophic lateral sclerosis type 6; Tremor, hereditary essential, 4
- P72S (p.Pro72Ser), ExAC rs753197353, TOPMed rs753197353, gnomAD rs753197353
- P72T (p.Pro72Thr), ExAC rs753197353, TOPMed rs753197353, gnomAD rs753197353, REVEL 0.47, CADD 23.20, Uncertain significance, Inborn genetic diseases
- P72P (p.Pro72Pro), rs756609265, gnomAD 16-31183883-C-G, CADD 13.00, SIFT 0.10
- Q73* (p.Gln73Ter), rs764487847, ClinGen CA395666508, ClinVar RCV000519344, ExAC rs764487847, AlphaMissense 0.14, MetaLR 0.60, Likely pathogenic
- Q73E (p.Gln73Glu), ExAC rs764487847, gnomAD rs764487847, Likely pathogenic
- Q73H (p.Gln73His), 1000Genomes rs150858484, ExAC rs150858484, gnomAD rs150858484, REVEL 0.43, CADD 22.40
- G74A (p.Gly74Ala), gnomAD rs1260300816, REVEL 0.22, CADD 19.70
- G74G (p.Gly74Gly), rs757454595, gnomAD 16-31183889-A-G, CADD 11.90, SIFT 0.03
- Y75Y (p.Tyr75Tyr), rs1426025939, gnomAD 16-31183892-T-C, CADD 11.00, SIFT 0.00
- S77L (p.Ser77Leu), ExAC rs779170261, gnomAD rs779170261, REVEL 0.45, CADD 23.90, Uncertain significance, Amyotrophic lateral sclerosis type 6; Tremor, hereditary essential, 4
- S77W (p.Ser77Trp), ExAC rs779170261, gnomAD rs779170261
- S77S (p.Ser77Ser), rs746093073, gnomAD 16-31183898-G-A, CADD 8.98, SIFT 0.34
- T78I (p.Thr78Ile), Ensembl rs2144107368, REVEL 0.10, CADD 13.20
- T78P (p.Thr78Pro), ExAC rs758426641, gnomAD rs758426641, REVEL 0.28, CADD 8.02
- p.Thr78 Tyr97del, gnomAD 16-31183897-CGACT, CADD 20.10
- T78T (p.Thr78Thr), rs780032205, gnomAD 16-31183901-T-C, CADD 9.19, SIFT 0.00
- G79C (p.Gly79Cys), ExAC rs746937494, gnomAD rs746937494
- G79D (p.Gly79Asp), rs2544251885, ClinGen CA395666598, ClinVar RCV002457758, Uncertain significance, Inborn genetic diseases
- G79G (p.Gly79Gly), rs535930927, gnomAD 16-31183904-C-T, CADD 8.58, SIFT 0.06
- G80S (p.Gly80Ser), rs776474571, ClinGen CA8023549, ClinVar RCV001055722, ClinVar RCV003363084, REVEL 0.29, CADD 22.10, Conflicting interpretations, Inborn genetic diseases; Amyotrophic lateral sclerosis type 6; Tremor, hereditar
- G80D (p.Gly80Asp), gnomAD 16-31183906-G-A, REVEL 0.51, MetaLR 0.70
- Y81C (p.Tyr81Cys), cosmic curated COSV54215, TOPMed rs2079219375, REVEL 0.50, CADD 26.60
- Y81H (p.Tyr81His), gnomAD rs1458159264, REVEL 0.42, CADD 25.90
- Y81Y (p.Tyr81Tyr), rs138534966, gnomAD 16-31183910-T-C, CADD 11.60, SIFT 0.00
Public FUS analysis runs
- FUS analysis run — FUS (759 variants) — completed 2026-08-10